Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

PHASE2CompletedINTERVENTIONAL

Enrollment

118

Participants

Timeline

Start Date

October 19, 2016

Primary Completion Date

April 5, 2022

Study Completion Date

July 10, 2024

Conditions

Prostate Cancer

Interventions

DRUG

Apalutamide

DRUG

Leuprolide

DRUG

Prednisone

DRUG

Abiraterone Acetate

Trial Locations (4)

Memorial Sloan-Kettering Cancer Center, New York

University of California, San Diego Moores Cancer Center, La Jolla

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02903368 - Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy | Biotech Hunter | Biotech Hunter